Noventi

Noventi is a well-established venture capital firm based in Newark, Delaware, with a long-standing commitment to global investment opportunities since its inception in 2002. The firm primarily focuses on early-stage technology companies, seeking out disruptive innovations across a diverse range of sectors. Their investment thesis centers on identifying and nurturing companies poised for significant growth and impact, particularly those leveraging cutting-edge advancements in their respective fields.

The firm's investment strategy is characterized by a keen interest in deep technology, with a pronounced emphasis on the biotechnology, advanced materials, and software sectors. Noventi actively participates in early-stage funding rounds, including Seed and Series A, and has demonstrated a willingness to continue supporting portfolio companies through later stages, such as Series B and C, as evidenced by their historical investments. This multi-stage support underscores their long-term partnership approach with founders.

Noventi boasts a robust portfolio of successful investments, demonstrating their ability to identify and back future industry leaders. Notable exits include OptiNose, which successfully went public, and QED Therapeutics, which was acquired by Eli Lilly for a substantial $680 million. Other significant investments include Adesis, acquired by Avantor, and their early support for companies like Incyte and InterDigital, which also achieved public market success. These examples highlight Noventi's track record in fostering companies from nascent stages to significant liquidity events.

With over two decades of experience in the venture capital landscape, Noventi has solidified its reputation as a discerning investor in disruptive technologies. Their consistent focus on high-potential, early-stage ventures, coupled with a strategic approach to supporting growth, positions them as a key player in the innovation ecosystem, particularly within the life sciences and advanced technology domains.